{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:07:20Z","timestamp":1782983240567,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Tesaro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00280-019-03774-w","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T23:38:54Z","timestamp":1548373134000},"page":"717-726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-0718","authenticated-orcid":false,"given":"Kathleen","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"issue":"1","key":"3774_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","volume":"24","author":"J Morales","year":"2014","unstructured":"Morales J, Li L, Fattah FJ, Dong Y, Bey EA, Patel M, Gao J, Boothman DA (2014) Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 24(1):15\u201328","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"9","key":"3774_CR2","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14(9):882\u2013892. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70240-7","journal-title":"Lancet Oncol"},{"issue":"22","key":"3774_CR3","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, Gonzalez-Martin A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA, Investigators E-ON (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375(22):2154\u20132164. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611310","journal-title":"N Engl J Med"},{"issue":"11","key":"3774_CR4","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1158\/1055-9965.EPI-13-0625","volume":"22","author":"EH Shinn","year":"2013","unstructured":"Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L, Woods ML, Patel P, Nick AM, Shahzad MM, Stone RL, Golden A, Atkinson E, Lutgendorf SK, Sood AK (2013) Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomark Prev 22(11):2102\u20132109. \n                    https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-0625","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3774_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejca.2016.03.008","volume":"60","author":"H Woopen","year":"2016","unstructured":"Woopen H, Inci G, Richter R, Chekerov R, Ismaeel F, Sehouli J (2016) Elderly ovarian cancer patients: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO). Eur J Cancer 60:101\u2013106. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2016.03.008","journal-title":"Eur J Cancer"},{"issue":"24","key":"3774_CR6","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2013.55.0459","volume":"32","author":"MK Accordino","year":"2014","unstructured":"Accordino MK, Neugut AI, Hershman DL (2014) Cardiac effects of anticancer therapy in the elderly. J Clin Oncol 32(24):2654\u20132661. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.55.0459","journal-title":"J Clin Oncol"},{"issue":"39","key":"3774_CR7","doi-asserted-by":"publisher","first-page":"25738","DOI":"10.18632\/oncotarget.25008","volume":"9","author":"J Duan","year":"2018","unstructured":"Duan J, Tao J, Zhai M, Li C, Zhou N, Lv J, Wang L, Lin L, Bai R (2018) Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget 9(39):25738\u201325749. \n                    https:\/\/doi.org\/10.18632\/oncotarget.25008","journal-title":"Oncotarget"},{"issue":"1","key":"3774_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"A Albini","year":"2010","unstructured":"Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102(1):14\u201325. \n                    https:\/\/doi.org\/10.1093\/jnci\/djp440","journal-title":"J Natl Cancer Inst"},{"key":"3774_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ctrv.2017.11.009","volume":"63","author":"C Coppola","year":"2018","unstructured":"Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N (2018) Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev 63:135\u2013143. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.009","journal-title":"Cancer Treat Rev"},{"key":"3774_CR10","unstructured":"ICH Harmonised Tripartite Guideline (2005) The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs E14. \n                    http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Guideline.pdf\n                    \n                  . Accessed 6 Sept 2018"},{"issue":"4","key":"3774_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00280-016-3124-5","volume":"78","author":"H Swaisland","year":"2016","unstructured":"Swaisland H, Plummer R, So K, Garnett S, Bannister W, Fabre MA, Dota C, Fielding A (2016) Olaparib does not cause clinically relevant QT\/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies. Cancer Chemother Pharmacol 78(4):775\u2013784. \n                    https:\/\/doi.org\/10.1007\/s00280-016-3124-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5 Suppl 1","key":"3774_CR12","first-page":"1","volume":"43","author":"MM Bednar","year":"2001","unstructured":"Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN (2001) The QT interval. Prog Cardiovasc Dis 43(5 Suppl 1):1\u201345","journal-title":"Prog Cardiovasc Dis"},{"issue":"22","key":"3774_CR13","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","volume":"25","author":"EL Strevel","year":"2007","unstructured":"Strevel EL, Ing DJ, Siu LL (2007) Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25(22):3362\u20133371. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.09.6925","journal-title":"J Clin Oncol"},{"issue":"1","key":"3774_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/157488610789869148","volume":"5","author":"MA Giorgi","year":"2010","unstructured":"Giorgi MA, Bolanos R, Gonzalez CD, Di Girolamo G (2010) QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Curr Drug Saf 5(1):54\u201357","journal-title":"Curr Drug Saf"},{"key":"3774_CR15","unstructured":"US Food and Drug Adminstration: Application number 208447Orig1s000\u2014NDA\/BLA multi-disciplinary review and evaluation of niraparib. Reference ID: 4074987. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208447Orig1s000MultidisciplineR.pdf\n                    \n                  . Accessed 12 Sept 2018"},{"key":"3774_CR16","unstructured":"Zejula\u00ae (niraparib) prescribing information (2018) TESARO IW, MA. \n                    https:\/\/www.zejula.com\/prescribing-information\n                    \n                  . Accessed 6 Sept 2018"},{"issue":"1","key":"3774_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/AOG.0000000000000917","volume":"126","author":"J Prat","year":"2015","unstructured":"Prat J, Oncology FCoG (2015) Staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication of guidelines from the International Federation of Gynecology and Obstetrics (FIGO). Obstet Gynecol 126(1):171\u2013174. \n                    https:\/\/doi.org\/10.1097\/AOG.0000000000000917","journal-title":"Obstet Gynecol"},{"issue":"3","key":"3774_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-017-3512-5","volume":"81","author":"K Moore","year":"2018","unstructured":"Moore K, Zhang ZY, Agarwal S, Burris H, Patel MR, Kansra V (2018) The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol 81(3):497\u2013503. \n                    https:\/\/doi.org\/10.1007\/s00280-017-3512-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3774_CR19","doi-asserted-by":"publisher","first-page":"E89","DOI":"10.1208\/aapsj080110","volume":"8","author":"H Fingert","year":"2006","unstructured":"Fingert H, Varterasian M (2006) Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management. AAPS J 8(1):E89\u2013E94. \n                    https:\/\/doi.org\/10.1208\/aapsj080110","journal-title":"AAPS J"},{"issue":"1","key":"3774_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-017-3455-x","volume":"81","author":"L Andel van","year":"2018","unstructured":"van Andel L, Rosing H, Zhang Z, Hughes L, Kansra V, Sanghvi M, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH (2018) Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients. Cancer Chemother Pharmacol 81(1):39\u201346. \n                    https:\/\/doi.org\/10.1007\/s00280-017-3455-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"3774_CR21","unstructured":"Lynparza\u00ae (olaparib) prescribing information (2018) AstraZeneca Pharmaceuticals (Wilmington, DE). \n                    https:\/\/www.azpicentral.com\/lynparza_tb\/pi_lynparza_tb.pdf#page=1\n                    \n                  . Accessed 24 Oct 2018"},{"key":"3774_CR22","unstructured":"Rubraca\u00ae (rucaparib) prescribing information (2018) Clovis Oncology, Inc. (Boulder, CO). \n                    http:\/\/www.clovisoncology.com\/media\/1094\/rubraca-prescribing-info.pdf\n                    \n                  . Accessed 6 Sept 2018"},{"key":"3774_CR23","unstructured":"European Medicines Agency: EMA\/CHMP\/238139\/2018\u2014Assessment report of the European Medicines Agency (2018) Procedure No. EMEA\/H\/C\/004272\/0000. \n                    https:\/\/www.ema.europa.eu\/documents\/assessment-report\/rubraca-epar-public-assessment-report_en.pdf\n                    \n                  . Accessed 6 Sept 2018"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03774-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03774-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03774-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T19:09:16Z","timestamp":1579806556000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03774-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["3774"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03774-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"12 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K.M. has served on the advisory borads of and received honoraria from AstraZeneca, Advaxis, Clovis, Genentech\/Roche, Immunogen, VBL Therapeutics, Janssen, Tesaro, Merck, Aravive, and OncoMed; K.M. also serves as the USA PI for the Tesaro-sponsored FIRST study using niraparib in front-line ovarian cancer and serves as the national PI for the niraparib study QUADRA. J.K.C. has received honoraria for a consulting role from Tesaro, Acerta, Aravive, Biodesix, Clovis, Janssen\/Johnson & Johnson, Oxigen\/Mateon, Roche\/Genentech, and AstraZeneca, has received honoraria for lectures including speakers\u2019 bureaus from AstraZeneca, Clovis, Merck, Roche\/Genentech, and Tesaro. A.S.S. has received grants from AbbVie, Amgen, Astellas Pharma Inc., Astex Pharmaceuticals Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Endocyte, Exelixis, Incyte, Merck, PharmaMar, Prima Biomed, Roche\/Genentech, TapImmune, and honoraria for advisory boards from Tesaro, Alexion, Aravive, Astex, AstraZeneca, Boehringer Ingelheim, Clovis, Janssen\/Johnson & Johnson, Merck, Mersano, Myriad, Oncoquest, Precision Therapeutics, and Roche\/Genentech. M.R.P. has nothing to disclose. T.C. is an employee of BioTel Research. W.G. and Z.Y.Z. employees of Tesaro, Inc and own stock\/have other ownership with Tesaro. Medical writing and copyediting support, funded by TESARO, Inc. and coordinated by Hemant Vyas, PhD, of TESARO, Inc, was provided by Swati Ghatpande, PhD, and Ann Marcos, MA, ELS, of Team 9 Science, LLC (Vaniam Group LLC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}